CPHI logo

CHINA PHARMA HOLDINGS INC

CPHINYSE AMERICAN
πŸ† #4640 by market capUS Equity
$0.66β–Ό $0.05 (βˆ’7.40%)
Market closed Β· at close
πŸ””
Track CPHI
Get earnings, price moves & breaking news on Telegram
Track
24hβ–Ό 7.4%
7dβ–Ό 8.8%
14dβ–Ό 8.5%
30dβ–Ό 25.6%
ytdβ–Ό 49.8%
1yβ–Ό 66.3%
🏦Market Cap
$27M
Small Cap
πŸ“ˆRevenue Growth (YoY)
-8.5%
Declining
πŸ“ŠGross Margin
-9.3%
Thin
πŸ’΅FCF Margin
-5.6%
Thin
βš–οΈP/S Ratio
7.8x
Fair
Otter Score
92
Very Good

Trading Snapshot

Day Range
$0.66 – $0.67
52-Week Range
$0.38 – $19.19
Volume
$1.81B
Avg Volume
$2.25B
Shares Outstanding
40.5M
Next Earnings
Nov 12, 2026

Fundamentals Snapshot

Annual Revenue
$4M
Last Q Revenue
$914,811
P/E Ratio
-0.7
P/S Ratio
7.8x
EPS (TTM)
$-1.04
Dividend Yield
0.00%

Why Investors Own CPHI

  • βœ“High-growth profile β€” revenue up +45.0% YoY with expanding US Equity exposure.
  • βœ“Healthy economics β€” 71% gross margin and 26% free-cash-flow margin.
  • βœ“New products and segments could unlock additional revenue streams.
⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

CPHI logo

CHINA PHARMA HOLDINGS INC

CPHI
Financial Trends
Revenue (TTM)The total money the company brought in from sales, before subtracting any costs.
$4Mβ–² +49.4% YoY
Gross Margin (TTM)Of every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
71.1%β–² +1.5% YoY
Operating Income (TTM)Profit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
$955,038β–² +49.4% YoY
Free Cash Flow (TTM)Cash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
$1Mβ–² +49.4% YoY
StockOtter Β· stockotter.space

About CHINA PHARMA HOLDINGS INC

China Pharma Holdings, Inc. (CPHI) specializes in the development, manufacturing, and marketing of both generic and branded pharmaceutical as well as biochemical products. The company primarily caters to hospitals and independent retailers throughout mainland China. Its comprehensive product portfolio encompasses diverse formulations, including powdered and liquid injectables, oral tablets, capsules, and cephalosporin-based oral solutions. CPHI's extensive range of medical solutions targets various health conditions. For neurological and cognitive health, it offers Cerebroprotein Hydrolysate injections to address memory decline and attention deficits, and Gastrodin injections for symptoms such as fatigue, lack of concentration, sleep disturbances, and traumatic brain syndromes. Cardiovascular and cerebrovascular treatments include Propylgallate and Ozagrel Sodium for conditions like cerebral thrombosis, coronary heart disease, and post-surgical recovery, as well as Alginic Sodium Diester injections targeting ischemic heart disease, cerebrovascular ailments, and hyperlipoproteinemia. Additionally, CPHI provides Bumetanide injections for edema management and Candesartan for hypertension. The company also produces a variety of anti-infective medications. These feature Roxithromycin dispersible tablets for throat infections (pharyngitis and tonsillitis), and Cefaclor dispersible tablets effective against conditions such as otitis media, lower respiratory tract infections, urinary tract infections, and skin/soft tissue infections. Other anti-infectives include Cefalexin capsules for acute tonsillitis, Andrographolide for sore throats stemming from upper respiratory tract infections, and Clarithromycin available in both granule and capsule forms. For pain and cold relief, CPHI offers sustained-release tablets containing Naproxen Sodium and Pseudoephedrine Hydrochloride. Furthermore, CPHI manufactures treatments for digestive disorders, including Hepatocyte growth-promoting factor, Tiopronin, Compound Ammonium Glycyrrhetate S, and Omeprazole. The product lineup extends to Vitamin B6 injections, Granisetron Hydrochloride injections for alleviating nausea and vomiting induced by cancer therapies (radiotherapy and chemotherapy), and dietary supplements like Noni Enzyme. Complementing its medical offerings, the company also provides health-related products such as sanitizers and protective masks. The company distributes its offerings via a network of third-party distributors, augmented by its own 16 sales offices and a team of around 1,000 sales professionals. Established in 1993, China Pharma Holdings, Inc. maintains its headquarters in Haikou, located in the People's Republic of China.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5β˜… and equally weighted (20%), averaged to a 0–100 score:πŸ’Ž Quality β€” gross marginπŸš€ Growth β€” revenue YoYβš–οΈ Valuation β€” P/S ratio⚑ Momentum β€” 30-day price changeπŸ’§ Dilution β€” 1-yr share issuance (buybacks score higher)
πŸ’ŽQualityβ˜…β˜…β˜…β˜…β˜…
πŸš€Growthβ˜…β˜…β˜…β˜…β˜…
βš–οΈValuationβ˜…β˜…β˜…β˜…β˜…
⚑Momentumβ˜…β˜…β˜…β˜…β˜…
πŸ’§Dilutionβ˜…β˜…β˜…β˜…β˜…
Overall Score
Very Good
92/100

Analyst Price Target

β“˜
Average Target
$0.68
β–² +2.4% Upside
High Target$0.74
Low Target$0.54
Based on 13 analysts

Latest News & Updates